Meta‑analyses of treatment standards for pancreatic cancer (Review)
- Authors:
- Jun Gong
- Richard Tuli
- Arvind Shinde
- Andrew E. Hendifar
-
Affiliations: Department of Internal Medicine, Samuel Oschin Cancer Center, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA, Department of Radiation Oncology, Samuel Oschin Cancer Center, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA, Department of Hematology and Oncology, Samuel Oschin Cancer Center, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA, Gastrointestinal and Neuroendocrine Malignancies, Samuel Oschin Cancer Center, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA - Published online on: December 18, 2015 https://doi.org/10.3892/mco.2015.716
- Pages: 315-325
-
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al: SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/2014.Accessed. March 21–2015 | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ryan DP, Hong TS and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM and Schulick RD: Surgical treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol. 16:1736–1744. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ and Pisters PW: Combined modality treatment of resectable and borderline resectable pancreas cancer, Expert consensus statement. Ann Surg Oncol. 16:1751–1756. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Castellanos JA and Merchant NB: Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol. 21:747–751. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kalser MH and Ellenberg SS: Pancreatic cancer. Histopathology. Arch Surg. 120:899–903. 1985.PubMed/NCBI | |
|
Bakkevold KE, Arnesjø B, Dahl O and Kambestad B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomized multicentre study. Eur J Cancer. 29A:698–703. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Gastrointestinal Tumor: StudyG roup: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 59:2006–2010. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, et al: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, et al: A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer. 101:908–915. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, et al: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 26:3503–3510. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Magorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, et al: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The mayo clinic experience (1975-2005). J Clin Oncol. 26:3511–3516. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, et al: Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo clinic collaborative study. Ann Surg Oncol. 17:981–990. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H and Neoptolemos JP: Pancreatic Cancer Meta-analysis Group. Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer. 92:1372–1381. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Boeck S, Ankerst DP and Heinemann V: The role of adjuvant chemotherapy for patients with resected pancreatic cancer, Systematic review of randomized controlled trials and meta-analysis. Oncology. 72:314–321. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, et al: Influence of resection margins and treatment on survival in patients with pancreatic cancer: Meta-analysis of randomized controlled trials. Arch Surg. 143:75–83. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP and Tu YK: Adjuvant treatments for resected pancreatic adenocarcinoma, A systematic review and network meta-analysis. Lancet Oncol. 14:1095–1103. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Z, Zhong W, Tan ZM, Wang LY and Yuan YH: Gemcitabine adjuvant therapy for resected pancreatic cancer, A meta-analysis. Am J Clin Oncol. 38:322–325. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ren F, Xu YC, Wang HX, Tang L and Ma Y: Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma, Continue or stop? Pancreatology. 12:162–169. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morganti AG, Falconi M, van Stiphout RG, Mattiucci GC, Alfieri S, Calvo FA, Dubois JB, Fastner G, Herman JM, Maidment BW III, et al: Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys. 90:911–917. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C and Koniaris LG: Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg. 10:689–697. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A and Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 230:776–784. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA and Willett CG: Fluorouracil based chemoradiation with either gemcitabine or fluorouracil chemotherapy following resection of pancreatic adenocarcinoma. 5-year analysis of the US intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 18:1319–1326. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Neoptolemos JP, Stocken DD, Smith Tudur C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D and Büchler MW: Adjuvant 5-fluorouracil and folinic acid vs. observation for pancreatic cancer Composite data from the ESPAC-1 and −3 (v1) trials. Br J Cancer. 100:246–250. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Raigani S, Ammori J, Kim J and Hardacre JM: Trends in the treatment of resectable pancreatic adenocarcinoma. J Gastrointest Surg. 18:113–123. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Sasaki H and Sueda T: Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol. 71:419–429. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, et al: Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study. J Clin Oncol. 32:504–512. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, Bartsch D, Klein J, Mansmann U, Jäger D, et al: Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 30:4077–4083. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fukutomi A, Uesaka K, Boku N, Kanemoto H, Konishi M, Matsumoto I, et al: JASPAC-01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol. 31(Suppl): 40082013. | |
|
Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V and Papamichael D: Adjuvant therapy for resectable pancreatic adenocarcinoma, Review of the current treatment approaches and future directions. Cancer Treat Rev. 40:78–85. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Evans DB, Ritch PS and Erickson BA: Neoadjuvant therapy for localized pancreatic cancer, Support is growing? Ann Surg. 261:18–20. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P and Sebastiano PD: Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer, A meta-analysis of prospective studies. Ann Surg Oncol. 19:1644–1662. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gillen S and Schuster T: MeyerZ um Büschenfelde CM, Friess H and Kleef J: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med. 7:e10002672010. View Article : Google Scholar : PubMed/NCBI | |
|
Assifi MM, Lu X, Eibl G, Reber HA, Li G and Hines OJ: Neoadjuvant therapy in pancreatic adenocarcinoma, A meta-analysis of phase II trials. Surgery. 150:466–473. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xu CP, Xue XJ, Liang N, Xu DG, Liu FJ, Yu XS and Zhang JD: Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer, A systematic review and meta-analysis. J Cancer Res Clin Oncol. 140:549–559. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, et al: The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 20((Suppl 3)): S500–S508. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cooper AB, Parmar AD, Riall TS, Hall BL, Katz MH, Aloia TA and Pitt HA: Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg. 19:80–87. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein W, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, et al: Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: Results of the first prospective randomized phase II trial. Strahlenther Onkol. 191:7–16. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bond-Smith G, Banga N, Hammond TM and Imber CJ: Pancreatic adenocarcinoma. BMJ. 344:e24762012. View Article : Google Scholar : PubMed/NCBI | |
|
Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff RA: Borderline resectable pancreatic cancer, Definitions, management and role of preoperative therapy. Ann Surg Oncol. 13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M, Macchia G, et al: A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 17:194–205. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW and Sandroussi C: A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 15:2059–2069. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Petrelli F, Coinu A, Borgonovo KF, Ghilardi M, Cabiddu M, Cremonesi M, Lonati V and Barni S: Resection rate with FOLFIRINOX-based neoadjuvant therapy in locally advanced/borderline resectable pancreatic cancer. A pooled analysis of published data. Ann Oncol. 25(Suppl 4): iv2402014. | |
|
Katz MHG, Crane CH and Varadhachary G: Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 24:105–112. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez NE, Prendergast C and Lowy AM: Borderline resectable pancreatic cancer, Definitions and management. World J Gastroenterol. 20:10740–10751. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Katz MHG, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, et al: Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118:5749–5756. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, Corrao S and Koch M: Neoadjuvant chemoradiotherapy for patients with borderline resectable pancreatic cancer, A meta-analytical evaluation of prospective studies. JOP. 14:618–625. 2013.PubMed/NCBI | |
|
Seufferlein T, Laethem JLV, Cutsem EV, Berlin JD, Büchler M, Cervantes A, et al: The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona. Ann Oncol. 25((Suppl 2)): ii1–ii4. 2014. View Article : Google Scholar | |
|
Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al: Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gurusamy KS, Kumar S, Davidson BR and Fusai G: Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2:CD0102442014.PubMed/NCBI | |
|
Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Büchler MW and Weitz J: Arterial resection during pancreatectomy for pancreatic cancer, A systematic review and meta-analysis. Ann Surg. 254:882–893. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 25:2607–2615. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI | |
|
Liang HL: Comparing gemcitabine-based combination chemotherapy with gemcitabine alone in inoperable pancreatic cancer: A meta-analysis. J Clin Oncol. 23:41102005.PubMed/NCBI | |
|
Xie DR, Liang HL, Wang Y and Guo SS: Meta-analysis of inoperable pancreatic cancer, Gemcitabine combined with cisplatin versus gemcitabine alone. Chin J Dig Dis. 7:49–54. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sultana A, Smith Tudur C, Cunningham D, Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer, Results of secondary end points analyses. Br J Cancer. 99:6–13. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xie DR, Liang HL, Wang Y, Guo SS and Yang Q: Meta-analysis on inoperable pancreatic cancer, A comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol. 12:6973–6981. 2006.PubMed/NCBI | |
|
Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F and Giannarelli D: Gemcitabine-based combinations for inoperable pancreatic cancer, Have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer. 110:525–533. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y and Zhang FC: A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol. 4:112011. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C, Ansari D, Andersson R and Wu DQ: Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol. 18:4944–4958. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Yan H, Liu W, Zhen H, Yang Y and Cao B: Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer, A meta-analysis of randomized controlled trials. PLoS One. 9:e1043462014. View Article : Google Scholar : PubMed/NCBI | |
|
Heinemann V, Labianca R, Hinke A and Louvet C: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer, Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 18:1652–1659. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, Andrieu JM and Oudard S: Meta-analysis of randomized trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging. 24:865–879. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials, Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF, Ma W and Zhang YD: Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer, Updated subgroup meta-analysis of overall survival. Jpn J Clin Oncol. 40:432–441. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P and Tagliaferri P: Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer, A meta-analysis of randomized trials. Eur J Cancer. 49:593–603. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eltawil KM, Renfrew PD and Molinari M: Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford). 14:260–268. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tian W, Ding W, Kim S, Xu X, Pan M and Chen S: Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer, A meta-analysis. Pancreatology. 13:415–422. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Zhang M and Luo S: Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer, A meta-analysis of prospective phase III studies. Tumor Biol. 35:11551–11558. 2014. View Article : Google Scholar | |
|
Li Q, Yuan Z, Yan H, Wen Z, Zhang R and Cao B: Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. Clin Ther. 36:1054–1063. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Van Loon K, Espinoza AM, Fogeman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, et al: Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 43:343–349. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yanagimoto H, Ishii H, Nakai Y, Ozaka M, Ikari T, Koike K, Ueno H, Ioka T, Satoi S, Sho M, et al: Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: Pooled analysis of three randomized studies. J Hepatobiliary Pancreat Sci. 21:761–766. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ku GY, Haaland BA, Ioka T, Isayama H, Nakai Y, Cheng AL, Okusaka T and de Lima Lopes G Jr: Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer. Revista Brasileira de Oncologia Clínica. 10:10–16. 2014. | |
|
Liu Y, Huang QK, Hong WD, Wu JM and Sun XC: The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer, Combined meta-analysis of efficacy and safety profile. Clin Res Hepatol Gastroenterol. 39:254–260. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP and Smith CT: Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer. 8:1922008. View Article : Google Scholar : PubMed/NCBI | |
|
Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic cancer: The Massachusetts General Hospital Cancer Center experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huguet F, Mukherjee S and Javle M: Locally advanced pancreatic cancer, The role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol). 26:560–568. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tempero MA, Malafa MP, Behrman SW, Benson AB III, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, et al: Pancreatic adenocarcinoma, Version 2.2014: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 12:1083–1093. 2014.PubMed/NCBI | |
|
Xie J, Yuan J and Lu L: Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma, A meta-analysis of randomized controlled trials. Diagn Pathol. 9:2142014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng J, Ren H and Hao J: Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer, A systematic review and meta-analysis of randomized controlled trials. PLoS One. 7:e408472012. View Article : Google Scholar : PubMed/NCBI | |
|
Hong GB, Zhou JX, Xu LF, Luo FT, Jang RJ, Luo JH and Chen YT: Meta-analysis on comparative study of curative effect between interventional therapy and conventional systemic venous chemotherapy in moderate and advanced pancreatic cancer. J Pract Radiol. 4:0222004. | |
|
Rombouts SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG and Molenaar IQ: Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg. 102:182–193. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil: The Gastrointestinal Study Group. Cancer. 48:1705–1710. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A and MacFarlane JK: Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas, A prospective randomized trial. J Can Assoc Radiol. 32:164–165. 1981.PubMed/NCBI | |
|
Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF and Moertel CG: Treatment of locally unresectable cancer of the stomach and pancreas, A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol. 3:373–378. 1985.PubMed/NCBI | |
|
Treatment of: locally unresectable carcinoma of the pancreas: C omparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Histopathology. J Natl Cancer Inst. 80:751–755. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ and Haller DG: Eastern Cooperative Oncology Group. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 62:1345–1350. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR and Benson AB III: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer. An Eastern Cooperative Oncology Group trial. J Clin Oncol. 29:4105–4112. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sultana A, Smith Tudur C, Cunningham D, Starling N, Tait D, Neoptolemos JP and Ghaneh P: Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 96:1183–1190. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Huguet F, Girard N, Guerche CS, Henneguin C, Mornex F and Azria D: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma, A qualitative systematic review. J Clin Oncol. 27:2269–2277. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Sun XJ, Jiang TH and Mao AW: Combined radiochemotherapy in patients with locally advanced pancreatic cancer, A meta-analysis. World J Gastronterol. 19:7461–7471. 2013. View Article : Google Scholar | |
|
Bernstein M, Kaubisch A, Rosenstein M, Aparo S, Garg MK, Kalnicki S, Guha C and Ohri N: Chemotherapy alone versus chemoradiation for unresectable pancreatic cancer, A meta-analysis. Int J Radiat Oncol Biol Phys. 90((Suppl 2014)): S363–S364. 2014. View Article : Google Scholar | |
|
Zhang X, Huang HJ, Feng D, Yang DJ, Wang CM and Cai QP: Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer? World J Gastroenterol. 20:17648–17655. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu CP, Shi J, Chen YX, Xie WF and Lin Y: Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer, A meta-analysis. Radiother Oncol. 99:108–113. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, et al: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 25:326–331. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B and Tempero MA: A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 68:809–816. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA and Crane CH: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 110:47–55. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, et al: Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol. 31(Suppl): LBA40032013. | |
|
Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM and Koong AC: Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 118:1119–1129. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fung MC, Takayama S, Ishiguro H, Sakata T, Adachi S and Morizane T: Chemotherapy for advanced or metastatic pancreatic cancer, Analysis of 43 randomized trials in 3 decades (1974-2002). Gan To Kagaku Ryoho. 30:1101–1111. 2003.(In Japanese). PubMed/NCBI | |
|
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, Huang YF, Mao C and Tang JL: Gemcitabine plus erlotinib for advanced pancreatic cancer, A systematic review with meta-analysis. PLoS One. 8:e575282013. View Article : Google Scholar : PubMed/NCBI | |
|
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chan K, Shah K, Lien K, Coyle D, Lam H and Ko YJ: A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS One. 9:e1087492014. View Article : Google Scholar : PubMed/NCBI | |
|
Gresham GK, Wells GA, Gill S, Cameron C and Jonker DJ: Chemotherapy regimens for advanced pancreatic cancer, A systematic review and network meta-analysis. BMC Cancer. 14:4712014. View Article : Google Scholar : PubMed/NCBI | |
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M and Barni S: Polychemotherapy or gemcitabine in advanced pancreatic cancer, A meta-analysis. Dig Liver Dis. 46:452–459. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Attard CL, Brown S, Alloul K and Moore MJ: Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Curr Oncol. 21:e41–e51. 2014.PubMed/NCBI |
